Conference Coverage

Speakers and attendees during the morning sessions on Wednesday December 11, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo Courtesy 2019 © MedMeetingImages/Todd Buchanan

SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in HER2+ Metastatic Breast...

Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in...

ASH 2019: Findings from Phase I Study of IMGN632 Shows Potential in AML and...

New safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients...
Speakers and attendees during Global Capacity Building Showcase at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center on Sunday December 8, 2019. Photo Courtesy 2019 © ASH/Nick Agro

First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of...

Data from a CD117-ADC, an antibody-drug conjugate being developed by Magenta Therapeutics, were presented at the 61st annual meeting...
General Views during at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center. Photo courtesey 2019 © ASH/Danny Morton.

ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin Lymphoma

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers...
Featured Image: American Society of Hematology | Annual Meeting. Courtesy: © 2017. American Society of Hematology. Used with permission.

What to Expect at ASH 2019: Seattle Genetics

With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the...
Featured Image: London Tower Bridge. Photo Courtesy: 2018 Fotolia

Zymeworks, Regeneron, Boehringer Ingelheim Pharma and Many Others are Betting on Antibody-Drug-Conjugates

Antibody-Drug -Conjugates (ADCs) have the potential to reduce off-target toxicities in patients by limiting the exposure of normal tissues...

What’s New in ADCs: 10th Annual World ADC Wrap-up

Hello ADC World:We have something a little different in store for today.  Today is a feature on the 10th...
General Views during at the American College of Rheumatology Annual Meeting, held November 8 - 13, 2019 in Atlanta, Georgia. Photo courtesy 2019 © ACR.

First Immune Reset with Single dose of CD45-ADC in Multiple Autoimmune Diseases

Data showing successful immune reset with a single dose of CD45-ADC, an antibody-drug conjugate, in models of three autoimmune...
Bayer researchers in one of Bayer’s cell culture laboratories in Berlin, Germany. Courtesy: Bayer

Antibody-drug Conjugates with Novel Kinesin Spindle Protein Inhibitor Payloads and a Tailor-made Linker Chemistry

With the approval of meanwhile five ADCs and more than 80 ADCs in clinical trials, the ADC landscape has...
Featured Image: Ado-trastuzumab emtansine (Kadcyla; Genentech/Roche), known as T-DM1 during. Courtesy: Genentech/Roche.

Pharmacokinetic Considerations to Maximize an ADC’s Therapeutic Index

The Antibody-drug Conjugate (ADC) field is poised for several significant advances in solid tumors as the industry has built...